Evidence map›Paper›PMID 40268813›Full record

ArticleJournal of neurology2025

Successful treatment of morvan syndrome with efgartigimod: report of two cases.

Peng Wang, Pengpeng Li, Ruojie He, Xiaoli Yao

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Peng WangDepartment of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases; National Key Clinical Department and Key Discipline of Neurology, Guangzhou, China.
Pengpeng LiDepartment of Neurology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Ruojie HeDepartment of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases; National Key Clinical Department and Key Discipline of Neurology, Guangzhou, China. herj@mail2.sysu.edu.cn.
Xiaoli YaoDepartment of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases; National Key Clinical Department and Key Discipline of Neurology, Guangzhou, China. yaoxiaol@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0003-2613-7956

Funding

Guangdong Province International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases 2020A0505020004Guangdong Provincial Clinical Research Center for Neurological Diseases 2020B1111170002National Natural Science Foundation of China 82271448Young Scientist Fund of the National Natural Science Foundation of China 82001332
6 · The paper itself

Abstract

objectiveMorvan Syndrome is a rare autoimmune-mediated clinical condition. This retrospective study aims at assessing the effectiveness and safety of intravenous Efgartigimod in 2 cases of the Morvan Syndrome with positive LGI1 and CASPR2 antibodies.

methodsWe reviewed the clinical manifestations, autoantibodies detection, electromyography (EMG) characteristics, treatments and follow-up outcomes in 2 patients of Morvan Syndrome with positive LGI1 and CASPR2 antibodies. Especially, we evaluated the therapeutic effectiveness and safety of intravenous Efgartigimod based on the improvement of symptoms, relapse conditions and adverse reactions.

resultsThe patient 1 was a 35-year-old female who presented with muscle tremors and pain in lower limbs. The serum VGKC, LGI1 and CASPR2 antibodies were positive. M-wave and muscle tremor discharges were observed in both gastrocnemius muscles with EMG examination. She was treated with efgartigimod (800 mg, once a week for 4 times), and the symptoms were almost alleviated at 6 months follow-up. The patient 2 was a 31 year-old female who presented with muscle soreness and weakness in four limbs. The serum VGKC, LGI1 and CASPR2 antibodies also were positive. M-wave discharges were observed with EMG examination. She was treated with efgartigimod (400 mg, once a week for 4 times), and follow-up at 6 months also showed recovery of muscle strength.

conclusionMorvan Syndrome is an antibody-related autoimmune syndrome with complex clinical manifestations. Our findings showed that the treatments of intravenous Efgartigimod could be effective and well tolerant in patients of Morvan Syndrome with LGI1 and CASPR2 antibodies.

Indexed as

SyringomyeliaAdultAutoantibodiesElectromyographyFemaleHumansIntracellular Signaling Peptides and ProteinsMembrane ProteinsNerve Tissue ProteinsTreatment OutcomeAutoantibodiesCNTNAP2 protein, humanIntracellular Signaling Peptides and ProteinsLGI1 protein, humanMembrane ProteinsNerve Tissue ProteinsAnti-CASPR2 autoantibodyAnti-LGI1 autoantibodyEfgartigimodMorvan syndromeM-wave after dischargeNeuropathic pain

Identifiers

PMID40268813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.